Veracyte Inc
Aperta
SettoreSettore sanitario
47.91 1.35
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
46.6
Massimo
47.91
Entrata | -20M 29M |
|---|---|
Vendite | -1.6M 139M |
P/E Media del settore | 45.019 49.052 |
EPS | 0.52 |
Margine di Profitto | 20.642 |
Dipendenti | 755 |
EBITDA | -17M 29M |
Raccomandazioni | Acquista |
|---|---|
Previsioni per 12 mesi | +0.51% upside |
Utili prossimi | 5 ago 2026 |
|---|
Capitalizzazione di Mercato | 1.1B 3.8B |
|---|---|
Apertura precedente | 46.56 |
Chiusura precedente | 47.91 |
Notizie sul Sentiment di mercato
By Acuity
50%
50%
146 / 342 Classifica in Healthcare
Veracyte Inc Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Chi Siamo Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.